This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Long term drug treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Antithyroid drugs are used in hyperthyroidism on the basis that the course may be self-limited, so suppression of the disease will tide the patient over until spontaneous remission occurs.

The treatment of choice is carbimazole - in the UK - or it's active metabolite - methimazole - in the USA. Propylthiouracil is an alternative.

Two regimens can be employed:

  • block-replace – a higher dose of anti thyroid drug (ATD) is used with concurrent replacement with levothyroxine
  • titrated – ATD is titrated over time to the lowest dose needed for maintaining a euthyroid state (1,2)

Remission rate for both regimens is around 50% in patients who continue the drugs between six and 18 months and then stop. In either regimen, patients may relapse once the treatment is stopped (1).

  • due to the higher incidence of side-effects associated with block and replace regimen, titration regimen is recommended as the first line approach in patients with Graves’ (2)

The side effects and efficacies of antithyroid drugs are similar and one may be substituted for another since cross-sensitivity between them is uncommon. Carbimazole is secreted in breast milk and therefore breast feeding is contraindicated during treatment.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.